Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Certepetide - Lisata Therapeutics

Next Previous
Drug Profile

Certepetide - Lisata Therapeutics

Alternative Names: CEND-1; Internalised-arginylglycylaspartic Acid Cyclic Peptide; iRGD; LSTA-1

Latest Information Update: 11 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DrugCendR
  • Developer Australasian Gastro-Intestinal Trials Group; Lisata Therapeutics; National Health and Medical Research Council Clinical Trials Centre; Qilu Pharmaceutical; The University of Kansas Cancer Center; University of Sydney
  • Class Antineoplastics; Cyclic peptides; Peptides
  • Mechanism of Action Capillary permeability stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Osteosarcoma; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Pancreatic cancer; Solid tumours
  • Phase I/II Colorectal cancer; Gastrointestinal cancer

Most Recent Events

  • 09 Apr 2024 Certepetide - Lisata Therapeutics receives Orphan Drug status for Osteosarcoma in USA
  • 21 Mar 2024 US FDA grants Rare Pediatric Disease Designation to Certepetide for the treatment of Osteosarcoma
  • 29 Feb 2024 Lisata Therapeutics announces intention to file for conditional approvals in multiple countries worldwide
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top